-ATPase. Furthermore, recent studies show that SEA0400 attenuates ischemia-reperfusion injury in the brain, heart, and kidney and radiofrequency lesion-induced edema in rat brain. These findings suggest that NCX plays a key role in ischemia-reperfusion injury and may be a target molecule for treatment of reperfusion injury-related diseases.
Introduction
The Na + -Ca 2+ exchanger (NCX) is involved in regulation of intracellular Ca 2+ concentration ([Ca 2+ ] i ) via the forward mode (Ca 2+ extrusion) or the reverse mode (Ca 2+ influx) (1 -6). NCX activity is dependent on membrane potential and transmembrane gradients of Na + and Ca
2+
.
Elevated intracellular Na
+ concentration, which is observed during ischemia, will cause NCX to function in the reverse mode, resulting in an increase in [Ca 2+ ] i (Fig. 1) . Because of these properties, NCX is considered to be a promising new target for drugs to reduce ischemic injury. Protocols to inhibit selectively NCX activity are essential for investigating the physiological and pathological roles of NCX. The antisense strategy has been successfully used in vitro, but not in vivo (7 -9) . NCX-knockout mice were produced, but they died before birth (10). Thus a selective inhibitor of NCX would be extensively useful for studies on the physiological and pathological roles of NCX. A variety of compounds have been reported to inhibit NCX activity, but their use was limited because of lack of selectivity for NCX (1, 4, 5) . Several peptides were also reported as potent and specific NCX inhibitors (1). Li et al. (11) synthesized a family of peptides corresponding to the calmodulin-binding autoinhibitory domain of NCX and demonstrated that XIP, one of these peptides, inhibits NCX activity with an IC 50 value of about 1.5 mM. XIP was the most selective inhibitor of NCX, but it did not appear to permeate through the cell membranes. In the circumstances, 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl] isothiourea (KB-R7943) was synthesized as a potent inhibitor of NCX (IC 50 , about 2 m M) (12). However, the results of previous studies do not support the selectivity of KB-R7943 for NCX (13 -15) . We have recently found that 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400), a newly synthesized compound (Fig. 2) , is the most potent and selective inhibitor of NCX so far reported (16). This compound has been identified by screening a compound library for inhibition of Na + -dependent Ca 2+ uptake into isolated cardiac sarcolemmal vesicles and cultured astrocytes. This review characterizes SEA0400 as a specific inhibitor of NCX and summarizes the recent studies on NCX using SEA0400. SEA0400 as a specific inhibitor of NCX SEA0400 is an extremely potent and selective inhibitor of NCX (Table 1) . In cultured neurons, astrocytes, and microglia, SEA0400 inhibits Na
uptake with IC 50 values of 5 -33 nM. With respect to selectivity, SEA0400 at 1 mM does not affect L-type Ca 2+ channel, N-type Ca 2+ channel, and Na + channel. This selectivity seems to be important for studies on the effect on ischemic injury since Ca 2+ and Na + channel inhibitors attenuate cerebral ischemic injury. Furthermore, SEA0400 at 3 m M does not affect other ion channels, receptors, and enzymes that are considered to be involved in key processes in ischemic disease, including Na + -H + exchange, K + channel, adrenoceptors, adenosine receptors, glutamate receptors, muscarinic acetylcholine receptors, leukotriene B 4 receptors, platelet activating factor receptors, phospholipases, lipoxygenasae, and inducible nitric oxide synthetase. SEA0400 does not affect store-operated Ca 2+ channels. In addition, Tanaka et al. (17) reported that SEA0400 is a selective inhibitor of NCX current in myocardial preparation. These observations suggest that SEA0400 is a highly specific inhibitor of NCX and that SEA0400 is a valuable new tool for elucidating the pathophysiological roles of NCX. However, Ruter et al. (18) using heart tubes prepared from embryos with NCX knocked out showed that SEA0400 had an effect on Ca 2+ signal even in the NCXdeficient preparation, although the exact mechanism for the effect on embryonic heart tubes is not known. This result suggests that SEA0400 should be used with caution.
The mammalian NCX forms a multigene family of highly homologous proteins comprising three isoforms, NCX1, NCX2, and NCX3 (1 -6). NCX1 is expressed in most tissues, whereas the expression of NCX2 and NCX3 is limited mainly to the brain and skeletal muscle. There are three isoforms of NCX in the brain, and they show developmental changes: the main isoform of immature rat brain is NCX1, whereas that of adult rat brain is NCX2 (19). SEA0400 inhibits Na + -dependent Ca 2+ uptake into NCX1 and NCX2 transfectants with IC 50 values of 56 and 980 nM, respectively, but it does not affect the NCX3 transfectant (20). SEA0400 stabilizes or modulates the transition of NCX into a Na + idependent inactive state (21, 22) . Furthermore, the inhibitory potency of SEA0400 is dependent on the intracellular Na + (21, 22). This inhibitory mechanism seems to be an ideal attribute when considering its potential utility against ischemia-reperfusion injury.
The protective effect of SEA0400 against reperfusion injury
Previous studies showed that the NCX inhibitor KB-R7943 attenuated ischemic injury in cardiac (23) and renal (24) preparations. However, it is obscure whether NCX is involved in the injury, since the specificity of the inhibitor is questionable. We found that SEA0400 attenuated Ca 2+ paradox-like injury in cultured astrocytes (16). This Ca 2+ paradox-like injury is mediated by an increase in [Ca 2+ ] i , resulting in production of reactive oxygen species (ROS), and SEA0400 blocks Ca 2+ paradox-induced ROS production, resulting in an antiapoptotic effect (25 -28). Furthermore, SEA0400 is effective in reducing infarct volume in the cerebral cortex after middle cerebral artery (MCA) occlusion. The finding suggests that NCX is involved in reperfusion injury in a MCA occlusion model, although the precise mechanism is not known. The similar protective effect of SEA0400 has been reported in in vitro and in vivo injury models of cardiac (29 -31) and renal (32) preparations. Furthermore, Luo et al. (33) have recently shown that SEA0400 prevented kinate-induced death of adult mouse retinal neurons, suggesting that the lethal Ca 2+ entry was via reverse operation of NCX.
Pharmacological effects of SEA0400
Disruption of Ca 2+ homeostasis in endothelial cells and astrocytes is considered to be responsible for dysfunction of blood-brain barrier permeability (34). We have found that administration of SEA0400 (3 and 10 mg / kg, i.v.) significantly attenuated the increase in brain water content and disruption of blood-brain barrier permeability after radiofrequency lesion in rats (35). The findings suggest that NCX plays a role in the generation of vasogenic edema accompanied by disruption of the blood-brain barrier. Iwamoto et al. (36) have recently found a new vascular effect of SEA0400. In vivo administration of SEA0400 suppressed the developmental hypertension and organ damage in an experimental hypertensive model. Furthermore, they showed using genetically NCX1-engineered mice that NCX1 contributes to hypertension. These findings suggest that NCX is a target molecule for treatment of some types of hypertension.
Conclusion
NCX may be one of molecular targets for improvement of Ca 2+ -mediated pathology. The most interesting point at the beginnings of NCX research was that NCX might be responsible for the pharmacological effect of cardiac glycosides, and its inhibitors had a positive inotropic effect in isolated guinea pig atria (37, 38). Although there is no inhibitor of NCX that is clinically used, the recent studies using SEA0400 suggest that the inhibitor will be used for treatment of ischemic events such as heart attack, stroke, and brain edema and hypertension. We hope that SEA0400 further contributes to clarification of the physiological and pathological roles of NCX. The inward NCX current in guinea pig cardomyocytes: IC50 = 40 nM (17)
The outward NCX current in guinea pig cardiomyocytes: IC50 = 32 nM (17) The functional proteins that are not affected by SEA0400 
